{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T23:03:57Z","timestamp":1783119837290,"version":"3.54.6"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010613","name":"Taipei Medical University Hospital","doi-asserted-by":"publisher","award":["113TMUH-TWS-03"],"award-info":[{"award-number":["113TMUH-TWS-03"]}],"id":[{"id":"10.13039\/501100010613","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010002","name":"Ministry of Education","doi-asserted-by":"publisher","award":["DP2-TMU-114-HIS-01"],"award-info":[{"award-number":["DP2-TMU-114-HIS-01"]}],"id":[{"id":"10.13039\/100010002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010002","name":"Ministry of Education","doi-asserted-by":"publisher","award":["DP2-TMU-114-O-06"],"award-info":[{"award-number":["DP2-TMU-114-O-06"]}],"id":[{"id":"10.13039\/100010002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.mayocp.2025.12.028","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T12:36:25Z","timestamp":1774701385000},"page":"727-742","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Antithrombotic Strategies in Advanced Chronic Kidney Disease: Real-World Comparison of Oral Anticoagulation Alone vs Dual Antithrombotic Therapy"],"prefix":"10.1016","volume":"101","author":[{"given":"Chih-Chin","family":"Kao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-An","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Yi","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0470-2184","authenticated-orcid":false,"given":"Sheng-Feng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10225","key":"10.1016\/j.mayocp.2025.12.028_bib1","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0140-6736(19)32977-0","article-title":"The global burden of chronic kidney disease","volume":"395","author":"Cockwell","year":"2020","journal-title":"Lancet"},{"issue":"9889","key":"10.1016\/j.mayocp.2025.12.028_bib2","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention","volume":"382","author":"Gansevoort","year":"2013","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.mayocp.2025.12.028_bib3","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1681\/ASN.2018050514","article-title":"Cardiovascular events after new-onset atrial fibrillation in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) study","volume":"29","author":"Bansal","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.mayocp.2025.12.028_bib4","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.028496","article-title":"Association of chronic kidney disease with atrial fibrillation in the general adult population: a nationwide population-based study","volume":"12","author":"Kim","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"16","key":"10.1016\/j.mayocp.2025.12.028_bib5","doi-asserted-by":"crossref","first-page":"8705","DOI":"10.3390\/ijms25168705","article-title":"Hallmarks for thrombotic and hemorrhagic risks in chronic kidney disease patients","volume":"25","author":"Saeed","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.mayocp.2025.12.028_bib6","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/jth.13904","article-title":"Chronic kidney disease and bleeding risk in patients at high cardiovascular risk: a cohort study","volume":"16","author":"Ocak","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"9","key":"10.1016\/j.mayocp.2025.12.028_bib7","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.3390\/biom11091309","article-title":"Coagulation abnormalities in renal pathology of chronic kidney disease: the interplay between blood cells and soluble factors","volume":"11","author":"Pavlou","year":"2021","journal-title":"Biomolecules"},{"issue":"4","key":"10.1016\/j.mayocp.2025.12.028_bib8","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/jth.15653","article-title":"Evaluation of novel coagulation and platelet function assays in patients with chronic kidney disease","volume":"20","author":"Abdelmaguid","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.mayocp.2025.12.028_bib9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.thromres.2023.04.016","article-title":"Global coagulation assays in patients with chronic kidney disease and their role in predicting thrombotic risk","volume":"226","author":"Lim","year":"2023","journal-title":"Thromb Res"},{"issue":"9921","key":"10.1016\/j.mayocp.2025.12.028_bib10","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.mayocp.2025.12.028_bib11","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/europace\/eut263","article-title":"Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events\u2013European Registry in Atrial Fibrillation (PREFER in AF)","volume":"16","author":"Kirchhof","year":"2014","journal-title":"Europace"},{"issue":"36","key":"10.1016\/j.mayocp.2025.12.028_bib12","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.mayocp.2025.12.028_bib13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jacc.2023.08.017","article-title":"2023 ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Joglar","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.mayocp.2025.12.028_bib14","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/europace\/euy174","volume":"21","author":"Lip","year":"2019","journal-title":"Europace"},{"issue":"11","key":"10.1016\/j.mayocp.2025.12.028_bib15","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jacc.2013.05.029","article-title":"Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention","volume":"62","author":"Lamberts","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.mayocp.2025.12.028_bib16","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/clc.22750","article-title":"Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: association with ischemic and bleeding events","volume":"40","author":"Lemesle","year":"2017","journal-title":"Clin Cardiol"},{"issue":"22","key":"10.1016\/j.mayocp.2025.12.028_bib17","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa2407362","article-title":"Edoxaban antithrombotic therapy for atrial fibrillation and stable coronary artery disease","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mayocp.2025.12.028_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.751359","article-title":"Antithrombotic therapy for chronic kidney disease patients with concomitant atrial fibrillation and coronary artery disease","volume":"8","author":"Lee","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"10.1016\/j.mayocp.2025.12.028_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"issue":"2","key":"10.1016\/j.mayocp.2025.12.028_bib20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.71079\/ASIDE.IM.03222516","article-title":"TriNetX and real-world evidence: a critical review of its strengths, limitations, and bias considerations in clinical research","volume":"1","author":"Nassar","year":"2025","journal-title":"ASIDE Intern Med"},{"issue":"1","key":"10.1016\/j.mayocp.2025.12.028_bib21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/ndt\/gfu015","article-title":"Drug adherence in chronic kidney diseases and dialysis","volume":"30","author":"Burnier","year":"2015","journal-title":"Nephrol Dial Transplant"},{"issue":"5-6","key":"10.1016\/j.mayocp.2025.12.028_bib22","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/jocn.13588","article-title":"Medication-taking behaviours in chronic kidney disease with multiple chronic conditions: a meta-ethnographic synthesis of qualitative studies","volume":"26","author":"Bartlett Ellis","year":"2017","journal-title":"J Clin Nurs"},{"issue":"5","key":"10.1016\/j.mayocp.2025.12.028_bib23","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/2047-783X-14-5-185","article-title":"Adherence to prescribed oral medication in adult patients undergoing chronic hemodialysis: a critical review of the literature","volume":"14","author":"Schmid","year":"2009","journal-title":"Eur J Med Res"},{"issue":"8","key":"10.1016\/j.mayocp.2025.12.028_bib24","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1093\/ndt\/gft027","article-title":"Impaired platelet P2Y12 inhibition by thienopyridines in chronic kidney disease: mechanisms, clinical relevance and pharmacological options","volume":"28","author":"Morel","year":"2013","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.mayocp.2025.12.028_bib25","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/jth.13211","article-title":"Antiplatelet effects of aspirin in chronic kidney disease patients","volume":"14","author":"Polzin","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.mayocp.2025.12.028_bib26","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1525-139X.2006.00179.x","article-title":"Platelet dysfunction and end-stage renal disease","volume":"19","author":"Kaw","year":"2006","journal-title":"Semin Dial"},{"issue":"5","key":"10.1016\/j.mayocp.2025.12.028_bib27","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1681\/ASN.0000000682","article-title":"Anticoagulation for atrial fibrillation in kidney failure: a call to arms","volume":"36","author":"De Vriese","year":"2025","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.mayocp.2025.12.028_bib28","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.kint.2021.03.020","article-title":"Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) conference","volume":"99","author":"Babitt","year":"2021","journal-title":"Kidney Int"},{"issue":"10206","key":"10.1016\/j.mayocp.2025.12.028_bib29","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist\u2013based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.mayocp.2025.12.028_bib30","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.mayocp.2025.12.028_bib31","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.mayocp.2025.12.028_bib32","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1904143","article-title":"Antithrombotic therapy for atrial fibrillation with stable coronary disease","volume":"381","author":"Yasuda","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.mayocp.2025.12.028_bib33","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1161\/CIRCULATIONAHA.118.036768","article-title":"Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation","volume":"139","author":"Matsumura-Nakano","year":"2019","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.mayocp.2025.12.028_bib34","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jacc.2024.12.030","article-title":"Anticoagulation and antiplatelet therapy for atrial fibrillation and stable coronary disease: meta-analysis of randomized trials","volume":"85","author":"Rashedi","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"38","key":"10.1016\/j.mayocp.2025.12.028_bib35","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"issue":"23","key":"10.1016\/j.mayocp.2025.12.028_bib36","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.121.054990","article-title":"Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial","volume":"146","author":"Pokorney","year":"2022","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.mayocp.2025.12.028_bib37","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1161\/CIRCULATIONAHA.122.062779","article-title":"A randomized controlled trial comparing apixaban with the vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study","volume":"147","author":"Reinecke","year":"2023","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.mayocp.2025.12.028_bib38","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1681\/ASN.2019060579","article-title":"Multicenter randomized controlled trial of vitamin K antagonist replacement by rivaroxaban with or without vitamin K2 in hemodialysis patients with atrial fibrillation: the Valkyrie study","volume":"31","author":"De Vriese","year":"2020","journal-title":"J Am Soc Nephrol"},{"issue":"21","key":"10.1016\/j.mayocp.2025.12.028_bib39","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"33","author":"Camm","year":"2012","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.mayocp.2025.12.028_bib40","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1055\/s-0042-1750385","article-title":"Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: executive summary of a European and Asia-Pacific Expert Consensus Paper","volume":"122","author":"Gorog","year":"2022","journal-title":"Thromb Haemost"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619626043326?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619626043326?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T13:09:58Z","timestamp":1782133798000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619626043326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0025619626043326"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2025.12.028","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antithrombotic Strategies in Advanced Chronic Kidney Disease: Real-World Comparison of Oral Anticoagulation Alone vs Dual Antithrombotic Therapy","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2025.12.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}